

01-26-04

PTO/SB/21 (03-03)  
Approved for use through 4/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p><b>TRANSMITTAL FORM</b></p> <p><i>(to be used for all correspondence after initial filing)</i></p>		Application Number	10/696,282
		Filing Date	October 29, 2003
		First Named Inventor	James M. Wilson et al
		Group Art Unit	1635
		Examiner Name	Brian A. Whiteman
		Attorney Docket Number	GNV31BUSA/UPN-K1774DIV1
Total Number of Pages In this Submission	11		

**ENCLOSURES**      *(check all that apply)*

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  <b>4-Copies of applications</b>
Remarks		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm or Individual Name	Howson and Howson Cathy A. Kodroff
Signature	
Date	January 23, 2004

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this date:			
Typed or printed name			
Signature		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

***If you need assistance in completing the form, call 1 -800-PTO-9199 (1-800-786-9199) and select option 2.***

**Express Mail No. EU531570363US**

**Customer No. 00270**



CUSTOMER NO. 00270

GNV31BUSA/UPN-K1774DIV1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of  
James M. Wilson

) Group Art Unit: 1635  
)  
) Examiner: Brian A. Whiteman

Appln. No. 10/696,282

) Confirmation No. 7675

Filed: October 29, 2003

For: ADENO-ASSOCIATED VIRUS  
SEROTYPE I NUCLEIC ACID  
SEQUENCES, VECTORS AND HOST  
CELLS CONTAINING SAME

)  
)  
)  
) January 23, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08A/B and this paper identify documents previously cited in parent application, US Patent Application No. 09/807,802, filed November 29, 2001, which is a national phase of PCT/US99/25694 filed November 2, 1999, which claims the benefit of the priority of US Patent Application No. 60/107,114, filed November 5, 1998.

According to 37 CFR § 1.98(d), Applicants have not enclosed copies of any US Patents, Publications or other documents listed herein, which listed items were previously cited by or submitted to the United States Patent and Trademark Office in prior parent US Patent Application No. 09/807,802, filed November 29, 2001. This application is relied upon for an earlier effective filing date under 35 USC § 120. The IDS submitted in the earlier application complies with paragraphs (a) through (c) of 37 CFR § 1.98(d).

Express Mail No. EU531570363US

## REMARKS

Listed below are previously filed, co-pending, co-owned U.S. Patent applications. This application and the present application are commonly owned: Copies of the application and claims are enclosed.

- (1) U.S. Patent Application No. 09/807,802, November 29, 2001
- (2) U.S. Patent Application No. 09/665,852, September 20, 2000
- (3) U.S. Patent Application No. 10/696,261, October 29, 2003
- (4) U.S. Patent Application No. 10/696,900, October 30, 2003


This Information Disclosure Statement is submitted within three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

The Examiner is respectfully requested to consider the enclosed document identified in this paper and in the attached Form PTO/SB/08A/B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON  
Attorneys for Applicant

By   
Cathy A. Rodroff  
Registration No. 33,980  
Spring House Corporate Center  
Box 457  
Spring House, PA 19477  
Phone: (215) 540-9200  
Fax: (215) 540-5818



PTO/SB/08B (04-03)  
Approved for use through 4/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office;  
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/696,282
				Filing Date	October 29, 2003
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
Examiner Name	Brian A. Whiteman				
Sheet	1	of	8	Attorney Docket Number	GNV31BUSA/ UPN-K1774DIV1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A	US-6,387,368 B1	05-14-2002	Wilson et al	
	B	US-6,274,354 B1	08-14-2001	Wilson et al	
	C	US-6,482,634 B1	11-19-2002	Wilson et al	
	D	US-6,475,769 B1	11-05-2002	Wilson et al	
	E	US-6,365,394 B1	04-02-2002	Gao et al	
	F	US-6,399,385 B1	06-04-2002	Croyle et al	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> <i>(if known)</i>					
	G	PCT WO03/093440	A2	11-13-2003	University of Florida		
	H	PCT WO03/092598	A2	11-13-2003	University of Florida		
	I	PCT WO98/11244	A2	03-19-1998	J. Chiorini		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 If possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)  
Approved for use through 4/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office;  
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/696,282
				Filing Date	October 29, 2003
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
				Examiner Name	Brian A. Whiteman
Sheet	2	of	8	Attorney Docket Number	GNV31BUSA/ UPN-K1774DIV1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	J	US-5,871,982 B1	02-16-1999	J. Wilson	
	K	US-6,258,595 B1	07-10-2001	G. Gao	
	L	US-6,274,354 B1	08-14-2001	J. Wilson	
	M	US-6,251,677 B1	06-26-2001	J. Wilson	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	N	PCT WO96/13598 A2	05-09-1996	J. Wilson		
	O	PCT WO98/10088 A1	03-12-1998	J. Wilson		
	P	PCT WO98/10086 A1	03-12-1998	J. Wilson		
	Q	PCT WO99/15677 A1	04-01-1999	J. Wilson		
	R	PCT WO99/14354 A1	03-25-1999	J. Wilson		
	S	PCT WO99/15685 A1	04-01-1999	J. Wilson		
	T	PCT WO99/47691 A1	09-23-1999	G. Gao		
	U	PCT WO00/55342 A1	09/21/2000	G. Gao		
	V	PCT WO00/75353 A1	12-14-2000	W. Xiao		
Examiner Signature				Date Considered		

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450**



PTO/SB/08B (04-03)  
 Approved for use through 4/30/2003. OMB 0651-0031  
 U.S. Patent and Trademark Office;  
 U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/696,282
				Filing Date	October 29, 2003
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
Examiner Name	Brian A. Whiteman				
Sheet	3	of	8	Attorney Docket Number	GNV31BUSA/ UPN-K1774DIV1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	W	US-6,156,303	12-05-2000	Russell et al	
	X	US-5,622,856	04-22-1997	Natsoulis	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					
	Y	PCT	WO01/23597 A2	04-05-2001	G. Gao		
	Z	PCT	WO01/23001 A2	04-05-2001	M. Croyle		
	AA	PCT	WO01/83692 A2	11-08-2001	M. Hildinger		
	BB	PCT	WO01/40455 A2	06-07-2001	G. Gao		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.  
 PTO/SB/08B (08-00)



Approved for use  
through 4/30/2003.  
OMB 0651-0031

U.S. Patent and Trademark Office;  
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/696,282
				Filing Date	October 29, 2003
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
				Examiner Name	Brian A. Whiteman
Sheet	4	of	8	Attorney Docket Number	GNV31BUSA/ UPN-K1774DIV1

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), coloumeousse number(s), publisher, city and/or country where published	T <sup>2</sup>
	CC	HAUCK ET AL, Generation and Characterization of Chimeric Recombinant AAV Vectors, Molecular Therapy, Vol. 7, No. 3, pp. 419-425, (March 2003)	
	DD	RABINOWITZ ET AL, Cross-Packaging of a Single Adeno-Associated Virus (AAV) Type 2 Vector Genome into Multiple AAV Serotypes Enables Transduction with Broad Specificity, Journal of Virology, Vol. 76, No. 2, pp. 791-801, (January 2002)	
	EE	HAUCK ET AL, Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1, Journal of Virology, Vol. 77, No. 4, pp. 2768-2774, (February 2003)	
	FF	ARRUDA ET AL, Safety and Efficacy of Factor IX Gene Transfer to Skeletal Muscle in Murine and Canine Hemophilia B Models by Adeno-Associated Viral Vector Serotype 1, Blood First Edition Paper, (September 11, 2003)	
	GG	E. RUTLEDGE ET AL, Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2, Journal of Virology, 72(1):309-319 (January , 1998)	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*



Approved for use  
through 4/30/2003.  
OMB 0651-0031  
U.S. Patent and Trademark Office;  
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/696,282
				Filing Date	October 29, 2003
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
				Examiner Name	Brian A. Whiteman
Sheet	5	of	8	Attorney Docket Number	GNV31BUSA/ UPN-K1774DIV1

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column number(s), publisher, city and/or country where published	T <sup>2</sup>
	HH	W. XIAO ET AL, Gene Therapy Vectors Based on Adeno-Associated Virus Type 1, Journal of Virology, 73(5):3994-4003 (May, 1999)	
	II	H. CHAO ET AL, Several Log Increase in Therapeutic Transgene Delivery by Distinct Adeno-Associated Viral Serotype Vectors, Molecular Therapy, 2(6):619-623 (December 2000)	
	JJ	R. KOTIN ET AL, Site-Specific Integration by Adeno-Associated Virus, Proc. Natl. Acad. Sci. USA, 87:2211-2215 (March, 1990)	
	KK	K. FISHER ET AL, Recombinant Adeno-Associated Virus for Muscle Directed Gene Therapy, Nature Medicine, 3(3):306-312 (March, 1997)	
	LL	X. XIAO ET AL, Efficient Long-Term Gene Transfer into Muscle Tissue of Immunocompetent Mice by Adeno-Associated Virus Vector, Journal of Virology, 70(11):8098-8108 (November, 1996)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.  
**SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.






Approved for use  
through 4/30/2003.  
OMB 0651-0031  
U.S. Patent and Trademark Office;  
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/696,282
				Filing Date	October 29, 2003
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
				Examiner Name	Brian A. Whiteman
Sheet	6	of	8	Attorney Docket Number	GNV31BUSA/ UPN-K1774DIV1

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column(s), volume(s), publisher, city and/or country where published	T <sup>2</sup>
	MM	R. SNYDER ET AL, Persistent and Therapeutic Concentrations of Human Factor IX in Mice After Hepatic Gene Transfer of Recombinant AAV Vectors, Nature Genetics, 16:270-276 (July, 1997)	
	NN	N. MUZYCZKA, Use of Adeno-Associated Virus as a General Transduction Vector for Mamalian Cells, Current Topics in Microbiology and Immunology, 158:97-129, (1992)	
	OO	R. SAMULSKI ET AL, Targeted Integration of Adeno-Associated Virus (AAV) into Human Chromosome 19, EMBO Journal, 10(12):3941-3950 (December, 1991)	
	PP	K. BERNIS, Parvoviridae: The Viruses and Their Replication, in B. N. Fields et al, Fields Virology, 3 <sup>rd</sup> ed., Vol. 2, Chapter 69, pp. 2173-2197 (Lippincott-Raven Publishers, Philadelphia, PA) (1996)	
	QQ	R. SNYDER ET AL, Features of the Adeno-Associated Virus Origin Involved in Substrate Recognition by the Viral Rep Protein, Journal of Virology, 67(10):6096-6104 (October, 1993)	
	RR	K. BERNIS, Parvovirus Replication, Microbiological Reviews, 54(3):316-329 (September, 1990)	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.  
**SEND TO: Commissioner for Patents, Alexandria VA 22313-1450**



Approved for use  
through 4/30/2003.  
OMB 0651-0031  
U.S. Patent and Trademark Office;  
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/696,282
				Filing Date	October 29, 2003
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
				Examiner Name	Brian A. Whiteman
Sheet	7	of	8	Attorney Docket Number	GNV31BUSA/ UPN-K1774DIV1

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), column number(s), publisher, city and/or country where published	T <sup>2</sup>	
	SS	R. SAMULSKI ET AL, Cloning of Adeno-Associated Virus into pBR322: Rescue of Intact Virus from the Recombinant Plasmid in Human Cells, Proc. Natl. Acad. Sci. USA, 79:2077-2081 (March, 1982)		
	TT	J. CHIORINI ET AL, Cloning of Adeno-Associated Virus Type 4 (AAV4) and Generation of Recombinant AAV4 Particles, Journal of Virology, 71(9):6823-6833 (September, 1997)		
	UU	S. MURAMATSU ET AL, Nucleotide Sequencing and Generation of an Infectious Clone of Adeno-Associated Virus 3, Virology, 221:208-217, (1996)		
	VV	C. BALAGUE ET AL, Adeno-Associated Virus Rep78 Protein and Terminal Repeats Enhance Integration of DNA Sequences into the Cellular Genome, Journal of Virology, 71(4):3299-3306 (April, 1997)		
	WW	R. SUROSKY ET AL, Adeno-Associated Virus Rep Proteins Target DNA Sequences to a Unique Locus in the Human Genome, Journal of Virology, 71(10):7951-7959 (October, 1997)		
	XX	X. XIAO ET AL, Gene Transfer by Adeno-Associated Virus Vectors into the Central Nervous System, Experimental Neurology, 144:113-124 (1997)		

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.  
**SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.**



Approved for use  
through 4/30/2003.  
OMB 0651-0031  
U.S. Patent and Trademark Office;  
U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/696,282
				Filing Date	October 29, 2003
				First Named Inventor	James M. Wilson
				Group Art Unit	1635
				Examiner Name	Brian A. Whiteman
Sheet	8	of	8	Attorney Docket Number	GNV31BUSA/ UPN-K1774DIV1

OTHER PRIOR ART-NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), collocation number(s), publisher, city and/or country where published	T <sup>2</sup>
	YY	ROSE ET AL, Microbiology, Vol. 546, Pages, 86-92, (1966)	
	ZZ	ANDERSON ET AL, Nature, Vol. 392, Pages, 25-30, (1998)	
	AAA	VERMA, Nature, Vol. 389, Pages 239-242, (1997)	
	BBB	ORKIN ET AL, Report and Recommendations of the Panel to Assess the NIH Investments in Research on Gene Therapy, issue by the National Institute of Health, (December 7, 1995)	

Examiner Signature	Date Considered
--------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, Alexandria, VA 22313-1450.**